Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Megestrol acetate |
Synonyms | |
Therapy Description |
Megace (megestrol acetate) is a progestin that activates progesterone receptor signaling and blocks luteinizing hormone signaling, which may lead to potential anti-estrogen and antitumor activities (PMID: 2471590). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Megestrol acetate | Megace | MGA|Linmegestrol|Magestin|Megestat|Megeron | Megace (megestrol acetate) is a progestin that activates progesterone receptor signaling and blocks luteinizing hormone signaling, which may lead to potential anti-estrogen and antitumor activities (PMID: 2471590). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05332483 | Phase I | Megestrol acetate | Study of Megestrol Acetate in Grade 2 Endometrioid Endometrial Cancer (MA-EEC) | Terminated | CAN | 0 |
NCT05255653 | Phase II | Olaparib Medroxyprogesterone Carboplatin Megestrol acetate Paclitaxel Cisplatin Durvalumab | Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) | Recruiting | NLD | GBR | FRA | CAN | 0 |
NCT05538897 | Phase Ib/II | Megestrol acetate Ipatasertib + Megestrol acetate | Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers | Recruiting | USA | 0 |
NCT03671811 | Phase II | Megestrol acetate + Pterostilbene Megestrol acetate | Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy | Active, not recruiting | USA | 0 |
NCT02269670 | Phase II | Tamoxifen Everolimus Megestrol acetate Letrozole Fulvestrant Anastrozole | Phase II Study of Everolimus Beyond Progression | Terminated | USA | 0 |